2-(2-(3-(3-(tert-Butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-4-(pyrimidin-5-yl)-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide

ID: ALA3798865

Chembl Id: CHEMBL3798865

PubChem CID: 127048088

Max Phase: Preclinical

Molecular Formula: C37H40ClF3N8O6S

Molecular Weight: 817.29

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)(C)NC(=O)Nc1nc(Cl)c(CCC2CCCCC2)n(CC(=O)Nc2cc(-c3cncnc3)ccc2C(=O)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1=O

Standard InChI:  InChI=1S/C37H40ClF3N8O6S/c1-36(2,3)47-35(53)46-32-34(52)49(29(31(38)45-32)16-9-22-7-5-4-6-8-22)20-30(50)44-28-17-23(24-18-42-21-43-19-24)10-15-27(28)33(51)48-56(54,55)26-13-11-25(12-14-26)37(39,40)41/h10-15,17-19,21-22H,4-9,16,20H2,1-3H3,(H,44,50)(H,48,51)(H2,45,46,47,53)

Standard InChI Key:  KCMYGZSFYPZFKJ-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3798865

    ---

Associated Targets(non-human)

NS3 NS3 protease (146 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NS3 NS3 (1121 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 817.29Molecular Weight (Monoisotopic): 816.2432AlogP: 6.56#Rotatable Bonds: 11
Polar Surface Area: 194.14Molecular Species: ACIDHBA: 10HBD: 4
#RO5 Violations: 2HBA (Lipinski): 14HBD (Lipinski): 4#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.23CX Basic pKa: 1.23CX LogP: 5.98CX LogD: 5.04
Aromatic Rings: 4Heavy Atoms: 56QED Weighted: 0.13Np Likeness Score: -1.37

References

1. Belfrage AK, Abdurakhmanov E, Kerblom E, Brandt P, Oshalim A, Gising J, Skogh A, Neyts J, Danielson UH, Sandström A..  (2016)  Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.,  24  (12): [PMID:27160057] [10.1016/j.bmc.2016.03.066]
2. Belfrage AK, Abdurakhmanov E, Åkerblom E, Brandt P, Alogheli H, Neyts J, Danielson UH, Sandström A..  (2018)  Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold.,  148  [PMID:29477077] [10.1016/j.ejmech.2018.02.032]

Source